Saadi Ryan H. - 10 Jul 2026 Form 4 Insider Report for Tevogen Bio Holdings Inc. (TVGN)

Reporting relationship: Chief Executive Officer, Director, 10%+ Owner
Issuer ticker: TVGN
Reported as of: 10 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jul 2026, 17:31:31 UTC
Prior SEC filing: 22 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Kirti Desai, Attorney-in-Fact

Key filing fact

Saadi Ryan H. filed Form 4 for Tevogen Bio Holdings Inc. (TVGN) on 10 Jul 2026.

Key facts

This page summarizes Saadi Ryan H.'s Form 4 filing for Tevogen Bio Holdings Inc. (TVGN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 10 Jul 2026, 17:31.

Change

Previous filing in this sequence was filed on 22 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002011728 Primary reporting owner

Saadi Ryan H.

Relationship: Chief Executive Officer, Director, 10%+ Owner
Address: C/O TEVOGEN BIO HOLDINGS INC., 15 INDEPENDENCE BLVD, STE 210, WARREN
Signature: /s/ Kirti Desai, Attorney-in-Fact
Signature date: 10 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TVGN transaction

Common Stock

Award

Transaction value
Shares: +1,220,000
Change %: +49%
Price: $0.000000^*
Shares after: 3,705,689
Date: 10 Jul 2026
Ownership: Direct
Footnotes: F1

TVGN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,878
Date: 10 Jul 2026
Ownership: By wife

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents a grant of restricted stock under the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan, which will vest ratably in four equal annual installments commencing on July 10, 2033, provided that the reporting person remains in service with the Issuer at such dates.